HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

PFE

Pfizer, Inc. (S&P 500)

Healthcare — Drug Manufacturers - General

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Buy 2.5 / 5 26 analysts
$25.25
+$0.58 (+2.35%)
Target: $28.75 (13.9%)
Sign in to add PFE to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$143.91B
P/E Ratio (TTM)19.27
Forward P/E8.92
EPS (TTM)$1.31
Dividend Yield6.97%
Profit Margin11.83%
Revenue Growth5.40%
ROE8.31%
Debt/Equity71.60
Recommendation Buy 2.5
Analyst Target$28.75
Analysts26
Indexes S&P 500

Technical Indicators

RSI (14)65.9
Beta0.31
SMA 20$24.51
SMA 40$24.93
52-Week High$28.75
52-Week Low$23.11
50-Day Avg$25.12
200-Day Avg$25.83
Avg Volume$41.01M
Volume$49.29M

Performance Analysis

BULLISH

PFE shows predominantly bullish signals based on its fundamentals and technicals.

~ Trading at 38% of its 52-week range.
+ RSI at 65.9 shows positive momentum.
~ Modest revenue growth of 5.4% year-over-year.
+ Wall Street consensus is "Buy" from 26 analysts.
+ Average analyst target of $28.75 implies 13.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 28, 2026 21:01 UTC

Back to Screener Export Report